Ahronian, Leanne G.
Tango Therapeutics (United States)
4 papers on CoChatORCID 0000-0001-7233-5879
Most cited papers
- Verified
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF -Mutant Colorectal Cancer through MAPK Pathway Alterations
Ahronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., Godfrey, J. T., Nishimura, K., Lynch, K. D., Mermel, C. H., et al. (2015) · Cancer Discovery
Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways
Cited by 322
- Verified
Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy
Ahronian, L. G., & Corcoran, R. B. (2017) · Genome Medicine
Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations
Cited by 67
- Verified
Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours
Corcoran, R. B., Do, K. T., Cleary, J. M., Parikh, A. R., Yeku, O. O., Weekes, C. D., Veneris, J., Ahronian, L. G., Mauri, G., Van Seventer, E. E., et al. (2019) · Annals of Oncology
Melanoma and MAPK PathwaysCell death mechanisms and regulation
Cited by 17
- Verified
TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy
Ahronian, L. G., Sahu, S., Zhang, M., Patel, A. S., Geng, K., Bhattacharya, R., Falchook, G. S., Goldman, J. W., Spira, A. I., Punekar, S. R., et al. (2025) · Cancer Research
Cancer Immunotherapy and BiomarkersHistone Deacetylase Inhibitors Research
Cited by 9
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free